Thomas Hamlyn

Tom joined OHE in October 2025 as an Economist. He holds a BSc in Economics from Lancaster University, and an MSc in International Health Policy (Health Economics) from the London School of Economics. 

Tom has a breadth of experience from within public policy and the pharmaceutical industry. He began his career as an economist within the UK government, using technical analysis to inform key strategic policy decisions across labour market and healthcare interventions. He has since worked in the pharmaceutical industry, tackling global value and access challenges in rare diseases, including his master’s dissertation which explored value-based pricing in rare diseases in the US and Germany using multi-criteria Decision analysis. Most recently he led strategic commercial analytics across the rare business unit portfolio for Takeda UK.